Our Vision

We are spearheading treatments that use the immune system to eliminate cancer, without chemotherapy or radiation. Our goal is to render today’s therapies obsolete until treating childhood cancer is no different than treating an everyday virus.

Accelerating Progress Toward Cures

  • Goal: Cure Neuroblastoma

    Dr. Julie Park is leading one of the world’s first clinical studies of immunotherapy for neuroblastoma – the deadliest childhood cancer.

  • We Need Your Help

    You can help bring an end to childhood cancer all over the world, by supporting our Strong Against Cancer fundraising initiative.

Participate in Research

Our researchers have started the first round of clinical trials exploring a potential cure.

Help us answer questions about childhood health and illness, and help other children in the future. Learn more.


Developing groundbreaking cancer treatments takes more than just the right ideas. It also takes the right people.

Please visit Seattle Children’s careers page to learn about current openings.

For information about potential opportunities in the Ben Towne Center, email us.

Latest News

BlueRock Therapeutics establishes key partnerships with leading experts in autoimmune disease (This story appeared in over 55 news outlets) – The Oklahoman
BlueRock Therapeutics, an engineered cell therapy company that aims to develop regenerative medicines for intractable diseases, announced the establishment of partnerships with Dr. Bruce Blazar of the University of Minnesota and Dr. Courtney Crane, principal investigator at the Ben Towne Center for Childhood Cancer Research at Seattle Children's.

Consolidative transplant after CAR T-cell therapy may benefit certain patients with acute lymphoblastic leukemia – 12.01.2018 – HemOnc Today
Consolidative hematopoietic stem cell transplant (HCST) after CD19-directed CAR T-cell therapy prolonged leukemia-free survival for certain pediatric and young adult patients with relapsed or refractory CD19-positive acute lymphoblastic leukemia, according to results of the PLAT-02 trial presented at ASH Annual Meeting and Exposition. However, investigators observed no significant difference in overall survival between patients who underwent consolidative HSCT and those who did not. This could be due to response to salvage therapy, according to researcher Dr. Corinne Summers, principal investigator in the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute. “Longer-term follow-up is needed, and I suspect that we may see a spread from those two lines eventually,” said Summers. “I’m happy that a lot of these patients who relapse after CAR T-cell therapy are salvageable with other therapies, but these are still very high-risk patients and we just need more time and more subjects under our belt.”

Researchers share key learnings from T-cell immunotherapy trials – 12.01.2018 – On the Pulse
Seattle Children’s recently enrolled its 200th immunotherapy patient, and now has nine CAR T-cell therapy trials targeting childhood cancers from leukemia to solid tumors. Seattle Children’s researchers are continuously discovering new best practices based on their experience in the trials, and as a result, shared six abstracts this weekend at the American Society of Hematology (ASH) Annual Meeting in San Diego. “It’s amazing to be at a place in our research where we’re learning from our existing trials, and immediately incorporating that vital intel into our new trials,” said Dr. Rebecca Gardner, oncologist and principal investigator for the PLAT-02 and PLAT-05 CAR T-cell immunotherapy trials. “We are also pleased to now offer several new trials to patients who would otherwise be out of treatment options. Our goal is to offer the best therapy possible, and to never let any patient reach the end of the line.” Key highlights include research on the potential benefit of bone marrow transplants by Dr. Corinne Summers, an oncologist and principal investigator in the Ben Towne Center for Childhood Cancer Research; research on boosting T cells from Dr. Colleen Annesley, an oncologist and principal investigator for the PLAT-03 trial; and Gardner’s research showing initial results from the PLAT-05 trial.